New Trends in the Science of Botulinum Toxin-A as Applied in Dystonia

REFERENCES

• Abbruzzese, G., & Berardelli, A. (2006). Neurophysiological effects of botulinum toxin type A. Neurotoxicity Research, 9, 109–114.
   PubMed Web of Science ®Google Scholar
• Alpiner, N. (2009). Botulinum toxin injections using computerised tomography guidance for enhanced anatomical localization. Presented at 70th Annual Assembly of the American Academy of Physical Medicine and Rehabilitation, 22–26 October, 2009, Austin, TX, USA, Poster 303.
   Google Scholar
• Aoki, R. (1999). Preclinical update on Botox® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. European Journal of Neurology, 6(Suppl 4), S3–S10.
   Web of Science ®Google Scholar
• Aoki, R., Merlino, G., Spanoyannis, A., & Wheeler, L. (1999). Botox® (botulinum toxin type A) purified neurotoxin complex prepared from the new bulk toxin retains the same preclinical efficacy as the original but with reduced immunogenicity. Neurology, 52(Suppl 2), A521–A522.
   Google Scholar
• Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Eitzen, E., Fine, A. D., (2001). Botulinum toxin as a biological weapon: Medical and public health management. JAMA, 285 (8), 1059–1070.
   PubMed Web of Science ®Google Scholar
• Atassi, Z. (2006). On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology, 152, 1891–1895.
   PubMed Web of Science ®Google Scholar
• Barbano, R. L. (2001). Needle EMG is useful. Muscle & Nerve, 24(11), 1567–1568.
   PubMed Web of Science ®Google Scholar
• Benecke, R., Jost, W. H., Kanovsky, P., Ruzicka, E., Comes, G., & Grafe, S. (2005). A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology, 64(1949–1951).
   PubMed Web of Science ®Google Scholar
• Bentivoglio, A. R., Fasano, A., Ialongo, T., Soleti, F., Lo-Fermo, S, & Albanese, A. (2009a). Fifteen-year experience in treating blepharospasm with Botox or Dysport: Same toxin, two drugs. Neurotoxicity Research, 15(3), 224–231.
   PubMed Web of Science ®Google Scholar
• Bentivoglio, A. R., Fasano, A., Ialongo, T., Soleti, F., Lo-Fermo, S, & Albanese, A. (2009b). Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. European Journal of Neurology, 16(3), 392–398.
   PubMed Web of Science ®Google Scholar
• Berardelli, A. (1999). Transcranial magnetic stimulation in movement disorders. Electroencephalography Clinical Neurophysiology, 51(Suppl.1), 276–280.
   Google Scholar
• Berardelli, A., Rothwell, J. C., Day, B. L., & Marsden, C. D. (1985). Pathophysiology of blepharospasm and oromandibular dystonia. Brain, 108(3), 593–608.
   PubMedGoogle Scholar
• Borodic, G. E., Cozzolino, D., & Ferrante, R. (1991). Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy. Opthalmic Plastic and Reconstructive Surgery, 7(1), 54–60.
   PubMed Web of Science ®Google Scholar
• Borodic, G., Johnson, E., Goodnough, M., & Schantz, E. (1996). Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology, 46, 26–29.
   PubMed Web of Science ®Google Scholar
• Depedibi, R., Unlu, E., Cevikol, A., Akkaya, T., Cakci, A., Cerekci, R., (2008). Ultrasound-guided botulinum toxin type A injection to the iliopsoas muscle in the management of children with cerebral palsy. Neurorehabilitation, 23(3), 199–205.
   PubMed Web of Science ®Google Scholar
• Deshpande, S., Gormley, M. E., & Carey, J. R. (2006). Muscle fiber orientation in muscles commonly injected with botulinum toxin: An anatomical pilot study. Neurotoxicity Research, 9(2,3), 115–120.
   PubMed Web of Science ®Google Scholar
• Dolimbek, B. Z., Aoki, K. R., Steward, L. E., Jankovic, J., & Atassi, M. Z. (2007). Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Molecular Immunology, 44, 1029–1041.
   PubMed Web of Science ®Google Scholar
• Dong, M., Liu, H., Tepp, W., Johnson, E. A., Janz, R., & Chapman, E. R. (2008). Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Molecular Biology of the Cell, 19, 5226–5237.
   PubMed Web of Science ®Google Scholar
• Dressler, D. (2004). Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Movement Disorders, 19(Suppl 8), S92–S100.
   PubMed Web of Science ®Google Scholar
• Dressler, D. (2009). Routine use of Xeomin® in patients previously treated with Botox®: Long term results. European Journal of Neurology, 16(Suppl 2), 2–5.
   PubMed Web of Science ®Google Scholar
• Eekhof, J., Aramideh, M., Bour, L., Hilgevoord, A., Speelman, H., & Ongerboer de Visser, B. (1996). Blink reflex recovery curves in blepharospasm, torticollis spasmodica, and hemifacial spasm. Muscle & Nerve, 19, 10–15.
   PubMed Web of Science ®Google Scholar
• Eisele, K-H., & Taylor, H-V. (2008). Dissociation of the 900kDa neurotoxin complex from C. botulinum under physiological conditions. Toxicon, 51, 10.
   PubMed Web of Science ®Google Scholar
• Farmer, S. F., Sheean, G. L., Mayston, M. J., Rothwell, J. C., Marsden, C. D., Conway, B. A., (1998). Abnormal motor unit synchronization of antagonist muscles underlies pathological co-contraction in upper limb dystonia. Brain, 121(5), 801–814.
   PubMedGoogle Scholar
• Frevert, J. (2009). Xeomin®: An innovative new botulinum toxin type A. European Journal of Neurology, 16(Suppl. 2), 11–13.
   PubMedGoogle Scholar
• Friday, D., Bigalke, H., & Frevert, J. (2002). In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. Naunyn-Schmiedebergs Archives of Pharmacology, 365(Suppl 2), R20.
   Google Scholar
• Fu, F-N., Sharma, S. K., & Singh, B. R. (1998). A protease-resistant novel hemagglutinin purified from type A Clostridium botulinum. Journal of Protein Chemistry, 7(1), 53–60.
   Google Scholar
• Fujinaga, Y. (2010). Interaction of botulinum toxin with the epithelial barrier. Journal of Biomedicine & Biotechnology, doi: 10.1155/2010/974943.
   PubMedGoogle Scholar
• Gelb, D. J., Yoshimura, D. M., Olney, R. K., Lowenstein, D. H., & Aminoff, M. J. (1991). Change in the pattern of muscle activity following botulinum toxin injections for torticollis. Annals of Neurology, 29, 370–376.
   PubMed Web of Science ®Google Scholar
• Giladi, N. (1997). The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. Journal of Neurological Sciences, 152, 132–135.
   PubMed Web of Science ®Google Scholar
• Goodmurphy, C. W. (1996). A comparative morphological study of two human facial muscles: The orbicularis oculi and the corrugator supercilii. Masters thesis, University of British Columbia, August 1996.
   Google Scholar
• Goodmurphy, C. W., & Ovalle, W. K. (1999). Morphological study of two human facial muscles: Orbicularis oculi and corrugator supercilii. Clinical Anatomy, 12, 1–11.
   PubMed Web of Science ®Google Scholar
• Grünewald, R., Yoneda, Y., Shipman, J., & Sagar, H. (1997). Idiopathic focal dystonia: A disorder of muscle spindle afferent processing? Brain, 120, 2179–2185.
   PubMed Web of Science ®Google Scholar
• Hadfield, A. T., Petsko, G., Lindo, P., & Singh, B. R. (1999). Preliminary crystallographic studies of a protease-resistant botulinum neurotoxin associated protein Hn-33. Acta Crystallographica, D55, 1537–1539.
   Google Scholar
• Hambleton, P., Pickett, A. M., & Shone, C. C. (2007). Botulinum toxin: From menace to medicine. In A. B. Ward & M. P. Barnes (eds.), Clinical Uses of BotulinumToxins., Cambridge, Cambridge University Press.
   Google Scholar
• Happak, W., Liu, J., Burggasser, G., Flowers, A., Gruber, H., & Freilinger, G. (1997). Human facial muscles: Dimensions, motor endplate distribution, and presence of muscle fibers with multiple motor endplates. Anatomical Record, 249, 276–284.
   PubMedGoogle Scholar
• Hunt, T., & Clarke, K. (2009). Potency evaluation of a formulated drug product containing 15-kD botulinum neurotoxin type A. Clinical Neuropharmacology, 32(1), 28–31.
   PubMed Web of Science ®Google Scholar
• Jackson, M. B., & Chapman, E. R. (2008). The fusion pores of Ca2+-triggered exocytosis. Nature Structural & Molecular Biology, 15(7), 684–689.
   PubMed Web of Science ®Google Scholar
• Jankovic, J. (2001). Needle EMG is rarely required. Muscle & Nerve, 24(11), 1568–1570.
   PubMed Web of Science ®Google Scholar
• Jones, S. J., Sheean, G., Ceballos-Baumann, A. O., & Marsden, C. D. (1995). Evidence for enhanced sensorimotor cortex excitability in dystonia (abstract). Electroencephalography and Clinical Neurophysiology, 94(Suppl. 1), S233.
   Google Scholar
• Jost, W. H., Blumel, J., & Grafe, S. (2007). Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs, 67(5), 669–683.
   PubMed Web of Science ®Google Scholar
• Kaji, R., Rothwell, J. C., Katayama, M., Ikeda, T., Kubori, T., Kohara, N., (1995). Tonic vibration reflex and muscle afferent block in writer's cramp. Annals of Neurology, 38(2), 155–162.
   PubMed Web of Science ®Google Scholar
• Kaňovský, P., Streitová, H., Dufek, J., & Rektor, I. (1997). Lateralization of the P22/N30 component of the median nerve in patients with cervical dystonia. Movement Disorders, 12, 553–560.
   PubMed Web of Science ®Google Scholar
• Kaňovský, P., Streitová, H., Dufek, J., Znojil, V., Daniel, P., & Rektor, I. (1999). Lateralization of the P22/N30 precentral cortical component of the median nerve somatosensory evoked potentials is different in patients with a tonic or tremulous form of cervical dystonia. Movement Disorders, 14, 642–651.
   PubMed Web of Science ®Google Scholar
• Karsai, S, & Raulin, C. (2007). Do different formulations of botulinum toxin type A really have different migration characteristics? Journal of Cosmetic Dermatology, 7(3), 230.
   Google Scholar
• Kim, D., Oh, B., & Paik, N. (2006). Central effect of botulinum toxin type A in humans. International Journal of Neuroscience, 116, 667–680.
   PubMed Web of Science ®Google Scholar
• Kukreja, R., Chang, T-W., Cai, S., Lindo, P., Riding, S., Zhou, Y., (2009). Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon, 53, 616–624.
   PubMed Web of Science ®Google Scholar
• Lamanna, C. (1959). The most poisonous poison. Science, 130, 763–772.
   PubMed Web of Science ®Google Scholar
• Lange, O., Bigalke, H., Dengler, R., Wegner, F., deGroot, M., & Wohlfarth, K. (2009). Neutralising antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothing? Clinical Neuropharmacology, 32(4), 213–218.
   PubMed Web of Science ®Google Scholar
• Lawrence, I., & Moy, R. (2009). An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A. Aesthetic Surgery Journal, 29(Suppl 6S), S66–S71.
   Google Scholar
• Lee, J. C., Yokata, K., Arimitsu, H., Hwang, H-J., Sakaguchi, Y., Cui, J., (2005). Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology, 113, 301–312.
   Google Scholar
• Lee, L. V., Maranon, E., Demaisip, C., Paralta, O., Borres-Icasiano, R., Arancillo, J., (2002). The natural history of sex-linked recessive dystonia parkinsonism of Panay, Philippines (XDP). Parkinsonism & Related Disorders, 9(1), 29–38.
   PubMed Web of Science ®Google Scholar
• Lim, E. C. H., Quek, A. M. L., & Seet, R. C. S. (2006). Botulinum toxin-A injections via electrical motor point stimulation to treat writer's cramp: Pilot study. Neurology, Neurophysiology, and Neuroscience, 4, 1–7.
   Google Scholar
• Lukban, M. B., Rosales, R. L., & Dressler, D. (2009). Effectiveness of botulinum toxin-A for upper and lower limb spasticity in children with Cerebral Palsy: A summary of evidence. Journal of Neural Transmission, 166, 319–331.
   Google Scholar
• Manganotti, P., Acler, M., Formaggio, E., (2010). Changes in cerebral activity after decreased upper-limb hypertonus: An EMG-fMRI study. Magnetic Resonance Imaging, 28(5), 646–652.
   PubMed Web of Science ®Google Scholar
• Mander, G., Fink, K., & Vey, M. (2009). Experimental conditions substantially influence botulinum toxin potency testing. Clinical Neuropharmacology, 32(4), 234.
   PubMed Web of Science ®Google Scholar
• Mink, J. W. (1996). The basal ganglia: Focused selection and inhibition of competing motor programs. Progress in Neurobiology, 50, 381–425.
   PubMed Web of Science ®Google Scholar
• Mohammadi, B., Buhr, N., Bigalke, H., Dengler, R., & Kollewe, K. (2009). A long-term follow-up of botulinum toxin A in cervical dystonia. Neurological Research, 31(5), 463–466.
   PubMed Web of Science ®Google Scholar
• Molloy, F. M., Shill, H. A., Kaelin-Lang, A., & Karp, B. I. (2002). Accuracy of muscle localization without EMG: Implications for treatment of limb dystonia. Neurology, 58(5), 805–807.
   PubMed Web of Science ®Google Scholar
• Murase. N., Kaji, R., Shimazu, H., (2000). Abnormal premovement gating of somatosensory input in writer's cramp. Brain, 123(9), 1813–1829.
   PubMedGoogle Scholar
• Nakashima, K., Rothwell, J. C., Day, B. L., Thompson, P. D., Shannon, K., & Marsden, C. D. (1989). Reciprocal inhibition between forearm muscles in patients with writer's cramp and other occupational cramps, symptomatic hemidystonia and hemiparesis due to stroke. Brain, 112, 681–697.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health (NIH) Consensus Development Program. (1990). Clinical Use of Botulinum Toxin. NIH Consensus Development Conference Statement, November 12–14, 1990. Accessed as http://consensus.nih.gov/1990/1990BotulinumToxin083html.htm, 20 April 2010.
   Google Scholar
• Naumann, M., & Jankovic, J. (2004). Safety of botulinum toxin type A: A systematic review and meta-analysis. Current Medical Research and Opinion, 20(7), 981–990.
   PubMed Web of Science ®Google Scholar
• Naumann, M., & Reiners, K. (1997). Long-latency reflexes of hand muscles in idiopathic focal dystonia and their modification by botulinum toxin. Brain, 120, 409–416.
   PubMed Web of Science ®Google Scholar
• Naumann, M., Abu-Shakra, S., Boodhoo, T., Miller-Messana, M. A., Demos, G., & Brin, M. F. (2009). A meta-analysis of neutralizing antibody conversion following a specific formulation of botulinum toxin type A (BoNTA, Allergan, Inc.). Movement Disorders, 24(Suppl 1), We-156.
   Google Scholar
• Naumann, M., Yakovleff, A., & Durif, F. (2002). A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. Journal of Neurology, 249(1), 57–63.
   PubMed Web of Science ®Google Scholar
• Panizza, M., Lelli, S., Nilsson, J., (1990). H-reflex recovery curve and reciprocal inhibition of H-reflex in different kinds of dystonia. Neurology, 40, 824–828.
   PubMed Web of Science ®Google Scholar
• Panjwani, N., O'Keeffe, R., & Pickett, A. (2008). Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. The Botulinum Journal, 1(1), 156–166.
   Google Scholar
• Pauri, F., Boffa, L., Cassetta, F., Pasqualetti, P., & Rossini, P. M. (2000). Botulinum toxin type-A treatment in spastic paraparesis: A neurophysiological study. Journal of Neurological Sciences, 181, 89–97.
   PubMed Web of Science ®Google Scholar
• Pickett, A. (2009). Dysport®: Pharmacological properties and factors that influence toxin action. Toxicon, 54(5), 683–689.
   PubMed Web of Science ®Google Scholar
• Pickett, A., & Caird, D. (2008). Comparison of type A botulinum toxin products in clinical use. Journal of Clinical Pharmacy and Therapeutics, 33, 327–328.
   PubMed Web of Science ®Google Scholar
• Pickett, A., & Perrow, K. (2010). Formulation composition of botulinum toxins in clinical use. Journal of Drugs in Dermatology, 9(9), 1085–1091.
   PubMed Web of Science ®Google Scholar
• Pickett, A., Dodd, S., & Rzany, B. (2008). Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. Journal of Cosmetic and Laser Therapy, 10, 181–183.
   PubMed Web of Science ®Google Scholar
• Poulain, B., Popoff, M. R., & Molgo, J. (2008). How do the botulinum neurotoxins block neurotransmitter release: From botulism to the molecular mechanism of action. The Botulinum Journal, 1(1), 14–87.
   Google Scholar
• Priori, A., Berardelli, A., Mercuri, B., & Manfredi, M. (1995). Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain, 118, 801–807.
   PubMed Web of Science ®Google Scholar
• Quartarone, A., Rizzo, V., Terranova, C., Morgante, F., Schneider, S., Ibrahim, N., (2009). Abnormal sensorimotor plasticity in organic but not in psychogenic dystonia. Brain, 132(10), 2871–2877.
   PubMedGoogle Scholar
• Racette, B. A., McGee-Minnich, L., & Perlmutter, J. S. (1999). Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: A blinded evaluation. Clinical Neuropharmacology, 22(6), 337–339.
   PubMed Web of Science ®Google Scholar
• Rao, S., Starr, R. L., Morris, M. G., & Lin, W-J. (2007). Variations in expression and release of botulinum neurotoxin in Clostridium botulinum type A strains. Foodborne Pathogens and Disease, 4(2), 201–207.
   PubMed Web of Science ®Google Scholar
• Reilly, J. A., Hallet, M., Cohen, L. G., Tarkka, I., & Dang, N. (1992). The N30 component of somatosensory evoked potentials in patients with dystonia. Electroencephalography and Clinical Neurophysiology, 84, 243–247.
   PubMedGoogle Scholar
• Ridding, M., Sheean, G., Rothwell, J. C., Inzelberg, R., & Kujirai, T. (1995). Changes in the balance between motor cortical excitation and inhibition in focal, task–specific dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 59, 493–498.
   PubMed Web of Science ®Google Scholar
• Roggenkamper, P., Jost, W. H., Bihari, K., Comes, G., & Grafe, S. (2006). Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. Journal of Neural Transmission, 113, 303–312.
   PubMed Web of Science ®Google Scholar
• Rona, S., Berardelli, A., Vacca, L., Inghilleri, M., & Manfredi, M. (1998). Alterations of motor cortical inhibition in patients with dystonia. Movement Disorders, 13, 118–124.
   PubMed Web of Science ®Google Scholar
• Rosales, R. L., & Chua-Yap, A. (2008). Evidence-based systematic review on the efficacy and safety of botulinum toxin therapy in post-stroke spasticity. Journal of Neural Transmission, 115(4), 617–623.
   PubMed Web of Science ®Google Scholar
• Rosales, R. L., & Dressler, D. (2010). On muscle spindles, dystonia and botulinum toxin. European Journal of Neurology, 17(Suppl. 1), 71–80.
   PubMed Web of Science ®Google Scholar
• Rosales, R. L., Arimura, K., Gamez, G., & Osame, M. (1995). X-linked dystonia-parkinsonism: Botulinum toxin therapy and stimulation single-fiber electromyography. Electroencephelography and Clinical Neurophysiology (Section of Electromyography and Motor Control), 97(Suppl.), S234–S235.
   Google Scholar
• Rosales, R. L., Arimura, K., Takenaga, S., & Osame, M. (1996). Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle & Nerve, 19, 488–496.
   PubMed Web of Science ®Google Scholar
• Rosales, R. L., Bigalke, H., & Dressler, D. (2006). Pharmacology of botulinum toxin: differences between type A preparations. European Journal of Neurology, 13(Suppl. 1), 2–10.
   PubMed Web of Science ®Google Scholar
• Rosales, R. L., Delgado, M. S., & Rosales, M. E. (2002). Spasticity, X-linked dystonia, parkinsonism and botulinum toxin A: The local scenario. Proceedings of the 3rd World Congress of Neurological Rehabilitation, Battistin, Dam, Tonin (eds), Monduzzi Editore, pp. 121–126.
   Google Scholar
• Rosales, R. L., Delgado, M., & Malicdan, M. (2004). Botulinum toxin A and muscle afferent block in X-linked dystonia-parkinsonism of Panay. Movement Disorders, 19(Suppl 9), S103–S104.
   Google Scholar
• Sakaguchi, G. (1983). Clostridium botulinum toxins. Pharmacy And Therapeutics, 19, 165–194.
   Web of Science ®Google Scholar
• Scott, A. (1985). Botulinum toxin treatment of strabismus. American Orthodontics Journal, 35, 28–29.
   Google Scholar
• Scott, A. B. (1981). Botulinum toxin injection of the eye muscles to correct strabismus. Transactions of the American Opthalmological Society, 79, 734–770.
   PubMedGoogle Scholar
• Scott, A. B. (2004). Development of botulinum toxin therapy. Dermatologic Clinics, 22, 131–133.
   PubMed Web of Science ®Google Scholar
• Scott, A. B., Rosenbaum, A., & Collins, C. C. (1973). Pharmacologic weakening of extraocular muscles. Investigative Ophthalmology, 12, 924–927.
   PubMedGoogle Scholar
• Senkarova, Z., Hlustik, P., Otruba, P., Herzig, R., & Kanovsky, P. (2009). Modulation of cortical activity in patients suffering from upper arm spasticity following stroke and treated with botulinum toxin A: An fMRI study. Journal of Neuroimaging, 20(1), 9–15.
   PubMed Web of Science ®Google Scholar
• Smith, T. J., Hill, K. K., Foley, B. T., Detter, J. C., Munk, A. C., Bruce, D. C., (2007). Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains; BoNT/A3, /Ba4 and /B1 clusters located within plasmids. PloS One, 12:e1271.
   Google Scholar
• Sohn, Y. H., & Hallett, M. (2004). Disturbed surround inhibition in focal hand dystonia. Annals of Neurology, 56, 595–599.
   PubMed Web of Science ®Google Scholar
• Stinear, C. M., & Byblow, W. D. (2004). Impaired modulation of intracortical inhibition in focal hand dystonia. Cerebral Cortex, 14 555–561.
   Google Scholar
• Sugawara, Y., Matsumura, T., Takegahara, Y., Jin, Y., Tsukasaki, Y., Takeichi, M., (2010). Botulinum haemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin. Journal of Cell Biology, 189(4), 691–700.
   PubMed Web of Science ®Google Scholar
• Sung, D. K., & Young, C. J. (2007). Localization of dystonic muscles with F18 FDG PET/CT in idiopathic cervical dystonia. Journal of Nuclear Medicine, 48(11), 1790–1795.
   PubMed Web of Science ®Google Scholar
• Tinazzi, M., Frasson, E., Polo, A., Tezzon, F., Bovi, P., Deotto, L., (1999). Evidence for an abnormal cortical sensory processing in dystonia: Selective enhancement of lower limb P37/N50 somatosensory evoked potential. Movement Disorders, 14(3), 473–480.
   PubMed Web of Science ®Google Scholar
• Trompetto, C., Curra, A., Buccolieri, A., Suppa, A., Abbruzzese, G., & Berardelli, A. (2006). Botulinum toxin changes intrafusal feedback in dystonia: A study with the tonic vibration reflex. Movement Disorders, 21, 777–782.
   PubMed Web of Science ®Google Scholar
• Valls-Sole, J., Tolosa, E. S., & Riber, G. (1991). Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm. Journal of Neurology, Neurosurgery and Psychiatry, 54, 310–313.
   PubMed Web of Science ®Google Scholar
• Wagman, J., & Bateman, J. B. (1953). Botulinum type A toxin: Properties of a toxic dissociation product. Archives of Biochemistry and Biophysics, 45, 375–383.
   PubMed Web of Science ®Google Scholar
• Walsh, R., & Hutchinson, M. (2007). Molding the sensory cortex: Spatial acuity improves after botulinum toxin treatment for cervical dystonia. Movement Disorders, 22, 2443–2446.
   PubMed Web of Science ®Google Scholar
• Ward, A. B., & Barnes, M. P. eds. (2007). Clinical Uses of Botulinum Toxins. Cambridge, Cambridge University Press.
   Google Scholar
• Wenzel, R. G. (2004). Pharmacology of botulinum neurotoxin serotype A. American Journal of Health System Pharmacy, 61(Suppl. 6), S5–S10.
   Google Scholar